CONGRESSES, CONFERENCES, SYMPOSIA

Пресс-релиз компании «Ф. Хоффманн-Ля Рош»

CONGRESSES, CONFERENCES, SYMPOSIA

 

Read in в PDF (RUS)pdficon

 

REFERENCES

  1. Goede V, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101–10. doi:10.1056/nejmoa1313984.
  2. Lamanna N, et al. Chronic Lymphocytic Leukemia and Hairy-Cell Leukemia. Cancer Management. Available from: http://www.cancernetwork.com/cancer-management/chronic-lymphocytic-leukemia-and-hairy-cell-leukemia.
  3. Ferlay J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49(6):1374–403. doi: 10.1016/j.ejca.2012.12.027.
  4. GLOBOCAN Europe (2012). Estimate cancer incidence, all ages: both sexes. Available from: http://globocan.iarc.fr/old/summary_table_pop-html.asp?selection=62968&title=Europe&sex=0&type=0&window=1&sort=0&submit=%C2%A0Execute.
  5. GLOBOCAN Europe (2012). Estimate cancer mortality, all ages: both sexes. Available from: http://globocan.iarc.fr/old/summary_table_pop-html.asp?selection=62968&title=Europe&sex=0&type=1&window=1&sort=0&submit =%C2%A0Execute.
  6. Goede V, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015:1–3. doi: 10.1038/leu.2015.14.

Report on the Meeting of Experts from Pathologicoanatomic Reference Centers for Diagnosing Hodgkin’s Lymphomas and Other CD30-Positive Lymphoproliferative Diseases in the Russian Federation

CONGRESSES, CONFERENCES, SYMPOSIA

Read in  PDF (RUS)pdficon

REFERENCES

  1. Ковригина А.М. Морфологическая и иммуногистохимическая дифференциальная диагностика лимфомы Ходжкина и крупноклеточных лимфом: Автореф. дис. ¼ д-ра биол. наук. М., 2006.
    [Kovrigina AM. Morfologicheskaya i immunogistokhimicheskaya differentsial’naya diagnostika limfomy Khodzhkina i krupnokletochnykh limfom. (Morphological and immunochemical differential diagnosis of Hodgkin’s lymphoma and large cell lymphoma.) [dissertation] Moscow; 2006. (In Russ)]
  2. Пивник А.В., Шаркунов Н.Н. Лимфома Ходжкина. Медицинский совет. 2013;5–6.
    [Pivnik AV, Sharkunov NN. Hodgkin’s lymphoma. Meditsinskii sovet. 2013:5–6. (In Russ)]
  3. www.lymphoma.ru.
  4. Птушкин В.В. Терапевтические подходы к пациентам с рецидивами и резистентным течением лимфомы Ходжкина. Практическая онкология. 2007;8(2):90–5.
    [Ptushkin VV. Treatment strategies for patients with relapsed/resistant Hodgkin’s lymphoma. Practical oncology. 2007;8(2):90–5. (In Russ)]
  5. Пархоменко Р.А. Перспективы таргетной терапии классической лимфомы Ходжкина. Вестник РНЦРР МЗ РФ. 2012;12.
    [Parkhomenko RA. Perspectives of the target therapy for classic Hodgkin’s lymphoma. Vestnik RNTsRR MZ RF. 2012;12. (In Russ)]
  6. Новик А.В. Таргетная терапия при лимфопролиферативных заболеваниях. Практическая онкология. 2010;11(3):131–42.
    [Novik AV. Target therapy for limphoproliferative diseases. Practical oncology. 2010;11(3):131–42. (In Russ)]

Materials of the 57th Annual Meeting of the American Society of Hematology (December, 2015; Orlando)

CONGRESSES, CONFERENCES, SYMPOSIA

AL Melikyan, DSci, IN Subortseva, PhD

For correspondence: Irina Nikolaevna Subortseva, PhD, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; Tel. +7(495)612-44-72; e-mail: soubortseva@yandex.ru

Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

Myeloproliferative Neoplasia: New Data

Received: February 13, 2016

Accepted: February 16, 2016

Read in PDF (RUS)pdficon

Materials of the 19th Russian Oncological Convention. Hematological Breakup Group “Radiation Therapy in Oncohematology” (November, 2015; Moscow)

CONGRESSES, CONFERENCES, SYMPOSIA

PAST AND FUTURE OF RADIATION THERAPY IN ONCOHEMATOLOGY

SI Tkachev, DSci

 

N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

Received: October 12, 2015

Accepted: December 23, 2015

Read in PDF (RUS)pdficon

REFERENCES

  1. Kostakoglu L, Cheson BD. State-of-the-art research on “lymphomas: role of molecular imaging for staging, prognostic evaluation, and treatment response”. Front Oncol. 2013;3:212. doi: 10.3389/fonc.2013.00212.
  2. Meignan M, Hutchings M, Schwartz L. Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. The Oncologist. 2015;20:890–5. doi: 10.1634/theoncologist.2015-0036.
  3. Omur O, Baran Y, Oral A, et al. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma. Diagn Interv Radiol. 2014;10:185–92. doi: 10.5152/dir.2013.13174.
  4. Barrington SF, Mikhaeel NG. When should FDG-PET be used in the modern management of lymphoma? Br J Haematol. 2014;164:315–28. doi: 10.1111/bjh.12601.
  5. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58. doi: 10.1200/jco.2013.53.5229.
  6. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 2014;32:3059–67. doi: 10.1200/jco.2013.54.8800.
  7. Cheng G, Alavi A. Value of 18F-FDG PET versus iliac biopsy in the initial evaluation of bone marrow infiltration in the case of Hodgkin’s disease: a meta-analysis. Nucl Med Commun. 2013;34(1):25–31. doi: 10.1097/mnm.0b013e32835afc19.
  8. Chen YK, Yeh CL, Tsui CC, et al. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: A meta-analysis. Clin Nucl Med. 2011;36:553–9. doi: 10.1097/rlu.0b013e318217aeff.
  9. Hutchings M. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy? Hematol Oncol Clin North Am. 2014;28(1):87–103. doi: 10.1016/j.hoc.2013.10.008.
  10. Gallamini A, Barringtom S, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematol. 2014;99(6):1107–13. doi: 10.3324/haematol.2013.103218.
  11. Moskowitz AJ, Schoder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284–92. doi: 10.1016/s1470-2045(15)70013-6.
  12. Haznedar R, Aki SZ, Akdemir OU, et al. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38:1046–53. doi: 10.1007/s00259-011-1738-8.
  13. Zamagni E, Nanni C, Tacchetti P, et al. Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. Clin Lymph Myel Leuk. 2014;14(3):e101–4. doi: 10.1016/j.clml.2013.12.014.
  14. Lee E, Lee H, Lee SJ, et al. Baseline F-18 FDG PET uptake of bone marrow as a survival predictor in patients with multiple myeloma. Clin Lymph Myel Leuk. 2015;15(Suppl. 3):e114–5. doi: 10.1016/j.clml.2015.07.295.
  15. Meignan M. FDG-PET as a biomarker in lymphoma: from qualitative to quantitative analysis. Hematol Oncol. 2015;33:38–41. doi: 10.1002/hon.2214.